Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | LevelStock.com: Antigen Express Cancer Vaccine Highlighted in Expert Opinion on Biological TherapyAntigen Express, Inc. today announced that AE37, a novel HER-2/neu-targeted vaccine for the treatment of breast, prostate, and other cancers, is reviewed in the September 2011 issue of Expert Opinion on Biological Therapy
By: LevelStock.com In the article titled "AE37: a novel T-cell-eliciting vaccine for breast cancer," senior author Col. George E. Peoples, M.D., F.A.C.S., Brooke Army Medical Center, focuses on the concept that AE37 vaccine's Ii-Key hybrid technology "has improved the potency of the AE37 vaccine to the point where it is capable of inducing immune responses even without immunoadjuvant," The article contrasts the unique ability of AE37 to stimulate CD4+ helper T cells with other therapeutic peptide vaccines that primarily stimulate CD8+ T cells, including E75 and GP2. Another difference is that AE37 can be used to treat twice the patient population than either E75 or GP2. The article further outlines many of the trials conducted to date with AE37, including Phase I clinical trials in both breast and prostate cancer and the ongoing controlled, randomized, and single-blinded Phase II trial in breast cancer. While preliminary, the authors noted an approximate 40% reduction in the rate of breast cancer recurrence at 17 months of median follow-up in patients treated with the AE37 peptide vaccine in the ongoing trial. The authors concluded that the AE37 vaccine is safe and well-tolerated with the ability to generate sustained, robust in vitro and in vivo immune response in vaccinated breast and prostate cancer patients. "We are pleased to see that as the data from clinical trials accumulate, AE37 continues to show that it is not only on track to achieve a positive endpoint in the treatment of breast cancer, but also shows clear advantages over other peptide and cancer vaccine strategies," Per trial design in the ongoing Phase II study, patients are being followed for clinical recurrences; About AE37 Antigen Express' novel Ii-Key Hybrid Preventive HER-2/neu Peptide Vaccine (AE37) is an "off-the-shelf" A controlled, randomized, and single-blinded Phase II clinical study of AE37 in HER-2 expressing breast cancer patients is currently underway to establish clinical efficacy. The study endpoint is a reduction in cancer relapse after two years compared to patients not receiving AE37. There are currently over 200 patients enrolled in the study with either node positive or high-risk node-negative breast cancer. While positive preliminary results suggested that statistically definitive results could be obtained in 2012, the company opted to enroll an additional 100 patients in early 2011 to ensure sufficient patient numbers. In particular, these additional patients are required to have low HER-2 expression levels such that they are not eligible for trastuzumab. It is anticipated that a planned Phase 3 trial will be conducted in this specific patient population. About Generex Biotechnology Corporation Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com. Cautionary Note Regarding Forward-Looking Statements This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," About LevelStock.com We are an investor community and investors relations website specializing in emerging growth stocks in today's Hot Sectors and providing a platform of services for SmallCap, MicroCap, NanoCap Companies. We encourage everyone to join our social media sites: Free Subscription For Our Newsletters: FaceBook: http://www.facebook.com/ Twitter: http://twitter.com/ LevelStock.com is not a registered investment advisor or broker-dealer. The information here is believed to be reliable, but not guaranteed to be accurate by LevelStock.com Please be advised that the information contained may or may not be complete and is solely for informational purposes only. Please read our full disclaimer for complete risks and disclosures http://www.levelstock.com/ End
Account Email Address Disclaimer Report Abuse
|
|